Open an account

PureTech Health

PRTC · LONDON

Price unavailable right now.

No price history for this range.

About PRTC

PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. The firm is engaged in the development of around 29 therapeutics and therapeutic candidates, including three that have been approved by the United States Food and Drug Administration. A number of these programs are advanced by the Company or its Founded Entities in various indications and stages of clinical development. Its primary programs include LYT-100 and LYT-200. Deupirfenidone (LYT-100) is being developed as a potential new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF). LYT-200 is an anti-galectin-9 monoclonal antibody (mAb) being developed for the treatment of hematological malignancies, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS), as well as solid tumors, including head and neck cancers, with a focus on metastatic disease.

Employees
90
Headquarters
Boston, Massachusetts
Listed
Jun 19, 2015
Sector
Health Care
Industry
Biotechnology
Website
puretechhealth.com

PRTC key statistics

This section is temporarily unavailable. Refresh to try again.

PRTC earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 55.4% on average.

  1. Q2 FY19: reported -$0.05 per share against an estimate of -$0.202
  2. Q2 FY20: reported -$0.36 per share against an estimate of -$0.101
  3. Q4 FY20: reported -$0.21 per share against an estimate of -$0.202
  4. Q2 FY21: reported -$0.50 per share against an estimate of -$0.1515
  5. Q2 FY22: reported -$0.08 per share against an estimate of -$0.202
  6. Q2 FY23: reported -$0.318 per share against an estimate of $0.0303
  7. Q2 FY24: reported -$0.21 per share against an estimate of -$0.303
  8. Q4 FY24: reported -$0.22 per share against an estimate of -$0.202

PRTC news

  • Press releaseBusiness Wire

    PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference

  • Press releaseBusiness Wire

    PureTech Announces Annual Results for Year Ended December 31, 2025

  • Press releaseBusiness Wire

    PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange

  • Press releaseBusiness Wire

    PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors

  • Press releaseBusiness Wire

    PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML)

  • Press releaseBusiness Wire

    PureTech Health: Notice of Results

  • Press releaseBusiness Wire

    PureTech Announces Publication of Phase 2b ELEVATE IPF Trial Results in The American Journal of Respiratory and Critical Care Medicine

  • Press releaseBusiness Wire

    PureTech Founded Entity Seaport Therapeutics Announces Positive Proof of Concept Topline Results from Ongoing Phase 1 Trial of GlyphAgo™ in Healthy Volunteers

Similar companies

Companies in the same industry as PureTech Health

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.